Formulation and in-vitro characterization of erythromycin ocular inserts

  • Shaik Harun Rasheed Department of Pharmaceutics, Srikrupa institute of Pharmaceutical Sciences, Siddipet - 502277, Telangana, India.
  • M. Samanvitha Department of Pharmaceutics, Srikrupa institute of Pharmaceutical Sciences, Siddipet - 502277, Telangana, India.
  • S.Y. Manjunath Department of Pharmaceutical Chemistry, Srikrupa institute of Pharmaceutical Sciences, Siddipet- 502277, Telangana, India.
Keywords: Erythromycin, Opthalmic inserts, Hydroxy Propyl Methyl Cellulose,, Gelatin, Ethyl Cellulose


Erythromycin has antibacterial activity and especially useful in the treatment of superficial infections involving conjunctivitis and/or cornea caused by organisms. Sustained drug therapies have more advantages than conventional. In the present study, an attempt was made to formulate sustained drug delivery system for Erythromycin in matrix type the formulations for Erythromycin containing 10%, 12%, and 14% w/v of Gelatin & Hydroxy propyl methylcellulose, and 14% , 16%, and 18% w/v for Ethyl cellulose were prepared by solvent casting method and evaluated for their average weight variation, thickness, drug content, in-vitro drug release and stability studies. An increase in average weight and thickness is due to an increase in polymer concentration. IR spectral studies were performed to confirm the interaction of drug with excipients. IR spectrum revealed that there is no incompatibility and no drug-polymer interactions. In vitro drug release studies were performed by vial method. Gelatin F09, HPMC F15 and EC F21 exhibited maximum average weight 16.66 ± 0.02, 10.81 ± 0.01 & 21.40 ± 0.01 mg respectively and thickness of 0.29 ± 0.01, 0.33± 0.06 and 0.43± 0.02mm respectively. The drug content was found to be 94.48, 92.87 & 90.26% respectively. The in-vitro drug release studies showed that increase in polymer content decreases the drug release from ocular inserts. Formulations containing 16 % and 18% w/v of EC showed sustained and almost complete drug release and dissolved 86.99% and 85.00 % over 14hours period was selected as an ideal formulation. The dissolution data of above formulation were subjected to first order, Higuchi’s and peppa’s equations. The linearity and slope indicates that the release of erythromycin from the films might have followed Peppa’s double log plot and non Fickian characteristics. Drug release from the ocular insert by diffusion controlled mechanism. Stability studies conducted for F20 formulation. The formulation showed satisfactory physical stability at 25oC and 40oC at 60% and 75% RH respectively. The physical appearance had not changed considerably. It can be concluded that formulation containing EC 18 % w/v has achieved the objectives of increased contact time, prolonged release, decreased frequency of administration and thus may improve the patient compliance.


Download data is not yet available.


Metrics Loading ...


Ammar, H. O., Salama, H. A., Ghorab, M., & Mahmoud, A. A. (2010). Development of dorzola-mide hydrochloride in situ gel nanoemulsion for ocular delivery. Drug development and industrial pharmacy, 36(11), 1330-1339.

Chrai, S. S., Makoid, M. C., Eriksen, S. P., & Robin-son, J. R. (1974). Drop size and initial dosing fre-quency problems of topically applied ophthalmic drugs. Journal of pharmaceutical sciences, 63(3), 333-338.

Robinson JC. (1993), Ophthalmic drug delivery systems. Vol-58 New York; Marcel dekker:29.

Hung, O. R., Whynot, S. C., Varvel, J. R., Shafer, S. L., & Mezei, M. (1995). Pharmacokinetics of inhaled liposome-encapsulated fentanyl. Anesthesiology: The Journal of the American Society of Anesthesi-ologists, 83(2), 277-284.

Pal Kaur, I., & Kanwar, M. (2002). Ocular prepara-tions: the formulation approach. Drug development and industrial pharmacy, 28(5), 473-493.

Goodman, L. S. (1996). Goodman and Gilman's the pharmacological basis of therapeutics (Vol. 1549). New York: McGraw-Hill.

Mundada, A. S., & Shrikhande, B. K. (2006). Design and evaluation of soluble ocular drug insert for controlled release of ciprofloxacin hydrochloride. Drug development and industrial pharmacy, 32(4), 443-448.

Jayaprakash, S., Dachinamoorthi, D., Ramkanth, S., Nagarajan, M., & Sangeetha, K. (2006). Formulation and evaluation of Gentamicin sulphate ocuserts. The Pharma Review, 131-34.

Kamath, U. R., Singh, U. V., & Udupa, N. (1993). Evaluation of ciprofloxacin hydrochloride ocular preparations. Indian Journal of Pharmaceutical Sci-ences, 55(4), 148-150.

Allen, D. J., DeMarco, J. D., & Kwana, K. C. (1972). Free films I: Apparatus and preliminary evaluation. Journal of pharmaceutical sciences, 61(1), 106-110.

Banker, G. S., Gore, A. Y., & Swarbrick, J. (1966). Water vapour transmission properties of free pol-ymer films. Journal of Pharmacy and Pharmacolo-gy, 18(7), 457-466.

Knaig JL, Goodmann H. J Pharma Sci. 1962;5:77

Manvi, F. V., Patil, M. B., Mastiholimath, V. S., & Rathod, R. (2004). Development and evaluation of ocular films of cromolyn sodium. Indian journal of pharmaceutical sciences, 66(3), 309.

How to Cite
Shaik Harun Rasheed, M. Samanvitha, & S.Y. Manjunath. (2020). Formulation and in-vitro characterization of erythromycin ocular inserts. International Journal of Research in Pharmaceutical Sciences and Technology, 2(2), 44-50.
Research Article